VanderbiltHealth.com: For Patients and Visitors
Vanderbilt University Medical Center: For Employees, Researchers, and Students

Published Research

Publications - Papers (Asterisk* indicates graduate student or postdoctoral fellow in Ann Richmond’s lab)

1.         Richmond A, Elmer WA. 1979. Purification of a mouse embryo extract component which enhances chondrogenesis in vitro. Developmental Biology. 1980 May;76(2):366-83. PMID6893034; NIHMS&PMCn/a

2.         Chawla RK, Slaer SM, Lawson DH, Murray TG, Schmidt R, Shoji M, Nixon DW, Richmond A, Rudman D. 1980. Elevated plasma and urinary guanosine 3':5' monophosphate and increased production rate in patients with neoplastic diseases. Cancer Research. 1980 Nov;40(11):3915-20. PMID6258769; NIHMS&PMCn/a

3.         Chawla RK, Lawson DH, Richmond A, Rudman D. 1980. Effect of plasma interalpha trypsin inhibitor and cancer-related glycoprotein EDC1 on phytohemagglutinin induced thymidine uptake in lymphocytes. Cancer Research. 1980 Nov;40(11):4187-91. PMID6162547; NIHMS&PMCn/a

4.         Richmond A, Lawson DH, Nixon DW, Stevens JS, Chawla RK. 1982. In vitro growth promotion in human-malignant melanoma cells by fibroblast growth factor. Cancer Research. 1982 Aug;42(8):3175-80. PMID6212117; NIHMS&PMCn/a

5.         Lawson DH, Nixon DW, Black ML, Tindall GT, Barnes DA, Faraj BA, Ali FM, Camp VM, Richmond A. 1983. Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma. Cancer. 1983 Apr 15;51(8):1541-5. PMID6186359; NIHMS&PMCn/a

6.         Richmond A., Lawson DH, Nixon DW, Chawla RK. 1983. Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Cancer Research. 1983 May;43(5):2106-12. PMID6600964; NIHMS&PMCn/a

7.         Richmond A., Lawson DH, Nixon DW, Chawla RK. 1985. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Research. 1985 Dec;45(12 Pt 1):6390-4. PMID3864531; NIHMS&PMCn/a

8.         Richmond A, Fine R, Murray D, Lawson DH, Priest J. 1986. Growth factor and cytogenetic abnormalities in nevus and malignant melanoma cells. Journal of Investigative Dermatology. 1986 Mar;86(3):295-302. PMID3745955; NIHMS&PMCn/a

9.         Richmond A, Thomas HG*. 1986. Purification of melanoma growth stimulatory activity. Journal of Cellular Physiology. 1986 Dec;129(3):375-84. PMID3465735; NIHMS&PMCn/a

10.     Lawson DH, Thomas HG*, Roy RGB, Gordon D, Nixon DW, Chawla RK, Richmond A. 1987. Preparation of a monoclonal antibody to a melanoma growth stimulatory activity released into serum free culture medium by Hs0294 malignant melanoma cells. Journal of Cellular Biochemistry. 1987 Jul;34(3):169-85. PMID3611199; NIHMS&PMCn/a

11.     Richmond A, Thomas HG*. 1988. Purification of Melanoma Growth Stimulatory Activity. (eds. R.C. Hickey, G.F. Saunders, D.S. Rivera). 1988 Yearbook of Cancer. 34:585‑587. PMID&NIHMS&PMCn/a

12.     Richmond A, Thomas HG*. 1988. Melanoma growth stimulatory activity, a novel growth factor with a tissue distribution not restricted to melanoma tissue. Journal of Cellular Biochemistry. 1988 Feb;36(2):185-98. PMID3356754; NIHMS&PMCn/a

13.     Thomas HG*, Richmond A. 1988. Immunoaffinity purification of melanoma growth stimulatory activity. Archives of Biochemistry and Biophysics. 1988 Feb 1;260(2):719-24. PMID3341763; NIHMS&PMCn/a

14.     Thomas HG*, Richmond A. 1988. High-yield purification of melanoma growth stimulatory activity. Molecular and Cellular Endocrinology. 1988 May;57(1-2):69-76. PMID3396757; NIHMS&PMCn/a

15.      Richmond A., Balentien E*, Thomas HG*, Flaggs G, Barton DE, Spiess J, Bordoni R*, Francke U, Derynck R. 1988. Molecular characterization of melanoma growth stimulatory activity, a growth factor structurally related to B-Thromboglobulin. EMBO Journal. 1988 Jul;7(7):2025-33. PMID2970963; NIHMS288441; PMC454478

16.     Priest J, Phillips C, Wang Y, Richmond A. 1988. Chromosome and growth factor abnormalities in melanoma. Cancer Genetics and Cytogenetics. 1988 Oct 15;35(2):253-62. PMID3141038; NIHMS&PMCn/a

17.     Bordoni R*, Thomas HG*, Richmond A. 1989. Interaction of melanoma growth stimulatory activity with other growth factors and regulation of messenger RNA expression in melanoma cells. Journal of Cellular Biochemistry. 1989 Apr;39(4):421-8. PMID2722970; NIHMS&PMCn/a

18.     Balentien E*, Han JH*, Thomas HG*, Wen DZ, Samantha AK, Zachariae CO, Griffin PR, Brachmann R, Wong WL, Matsushima K, Richmond A, Derynck R. 1990. Recombinant expression, biochemical characterization, and biological activities of the human MGSA/gro protein. Biochemistry. 1990 Nov 6;29(44):10225-33. Erratum in: Biochemistry 1991 Jan 15;30(2):594. PMID2271650; NIHMS&PMCn/a

19.     Baker NE, Kucero G, Richmond A. 1990. Nucleotide sequence of the human melanoma growth stimulatory activity (MGSA) gene. Nucleic Acids Research 1990 Nov 11;18(21):6453. PMID2129556; NIHMS&PMCn/a

20.     Balentien E, Mufson BE, Shattuck RL, Derynck R, Richmond A. 1991. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene. 1991 Jul;6(7):1115-24. PMID1861861; NIHMS&PMCn/a

21.     Richmond A. 1991. The pathogenic role of growth factors in melanoma. Seminars in Dermatology (ed. R.M. Fine). 1991 Sep;10(3):246-55. PMID:1931574; NIHMS&PMCn/a

22.     Bordoni R*, Fine R, Murray D, Richmond A. 1991. Characterization of the autocrine role of MGSA in normal melanocytes and malignant melanoma. Journal of Cellular Biochemistry. 1991 Dec;44(4):207-219. PMID2095366; NIHMS&PMCn/a

23.     Cheng QC, Han JH*, Thomas HG*, Balentien E*, Richmond A. 1992. The melanoma growth stimulatory activity receptor consists of two proteins. Ligand binding results in enhanced tyrosine phosphorylation. J Immunol. 1992 Jan 15;148(2):451-6. PMID1729365; NIHMS&PMCn/a

24.     Tettelbach W, Nanney L, Ellis D, King L, Richmond A. 1993. Localization of MGSA/GRO protein in cutaneous lesions.J Cutan Pathol. 1993 Jun;20(3):259-66. PMID8366215; NIHMS&PMCn/a

25.     Jaffe GJ, Richmond A., VanLe L, Shattuck RL*, Cheng QC, Wong F, Roberts W. 1993. Expression of three forms of melanoma growth stimulating activity (MGSA)/Gro in human retinal pigment epithelial cells. Investigative Ophthalmology & Visual Science. 1993 Aug;34(9):2776-85. PMID8344798; NIHMS&PMCn/a

26.     Shattuck RL*, Wood LD*, Jaffe GJ, Richmond A. 1994. High basal transcription through the NF-kB element results in accumulation of MGSA/GRO in human melanoma. Molecular and Cellular Biology. 1994 Jan;14(1):791-802. Erratum in: Mol & Cell Biol 1995 Feb;15(2):1136. PMID8264646; NIHMS&PMCn/a

27.     Mueller SG*, Schraw WP, Richmond A. 1994. Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells. J Biol Chem. 1994 Jan 21;269(3):1973-80. PMID8294449; NIHMS&PMCn/a

28.     Mueller SG*, Schraw WP, Richmond A. 1995. Activation of protein kinase C enhances the phosphorylation of the type B interleukin-8 receptor and stimulates its degradation in non-hematopoietic cells. J Biol Chem. 1995 May 5;270(18):10439-48. PMID7737978; NIHMS&PMCn/a

29.     Schraw WP, Richmond A. 1995. Melanoma growth stimulatory activity signaling through the class II Interleukin-8 receptor enhances the tyrosine phosphorylation of Crk-associated substrate, p130, and a 70-kilodalton protein. Biochemistry. 1995 Oct 24;34(42):13760-7. PMID7577968; NIHMS&PMCn/a

30.     Wood LD*, Farmer AA, Richmond A. 1995. HMGI(Y) and Sp1 in addition to NF-kB regulate transcription of the MGSA/GRO alpha gene. Nucleic Acids Research. 1995 Oct 25:23(20):4210-19. PMID7479086; NIHMS&PMCn/a

31.     Nanney LB, Mueller SG*, Bueno R, Peiper SC, Richmond A. 1995. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair. Am J Pathol. 1995 Nov;147(5):1248-60. PMID7485389; NIHMS&PMCn/a

32.     Wood LD* and Richmond A. 1995. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO gene requires both NF-kB and Novel Constitutive Factors. Journal of Biological Chemistry. 1995 Dec 22:270(51):30619-26. PMID8530498; NIHMS&PMCn/a

33.     Shattuck-Brandt RL*, Wood LD*, Richmond A.. 1997. Identification and characterization of an MGSA/GRO pseudogene. DNA Sequence. 1997;7(6):379-386. PMID9524820; NIHMS&PMCn/a

34.     Mueller SG*, White JR, Schraw WP, Lam V, Richmond A. 1997. Ligand-induced desensitization of the human CXC chemokine receptor-2 is modulated by multiple serine residues in the carboxyl-terminal domain of the receptor. J Biol Chem. 1997 Mar 28;272(13):8207-14. PMID9079638; NIHMS&PMCn/a

35.     Shattuck-Brandt RL*, Richmond A. 1997. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res. 1997 Jul 15;57(14):3032-9. PMID9230219; NIHMS&PMCn/a

36.     Owen JD*, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R*, Richmond A. 1997. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int J Cancer. 1997 Sep 26;73(1):94-103. PMID9334815; NIHMS&PMCn/a

37.     Luan J*, Shattuck-Brandt R*, Haghnegahdar H, Owen JD*, Strieter R, Burdick M, Nirodi C, Beauchamp D, Johnson KN, Richmond A. 1997. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression.. Journal Leukocyte Biology. 1997 Nov;62(5):588-97. PMID9365113; NIHMS&PMCn/a

38.     Yang W, Schraw WP, Mueller SG, Richmond A. 1997. Interruption of G protein-coupling in CXCR2 does not alter ligand binding, but eliminates ligand-activation of GTPgamma35S binding, calcium mobilization, and chemotaxis. Biochemistry. 1997 Dec 9;36(49):15193-200. PMID9398246; NIHMS&PMCn/a

39.     Tang T*, Owen JD*, Du J, Walker CL, Richmond A. 1998. Molecular cloning and characterization of a mouse gene with homolog to the Duffy-antigen receptor for chemokines. DNA Sequence. 1998; 9(3): 129-143. PMID10520743; NIHMS&PMCn/a

40.     Nanney LB, Skeel A, Luan J*, Polis S, Richmond A, Wang MH, Leonard EJ. 1998. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. Journal Investigative Dermatology. 1998 Oct;111(4):573-81. PMID9764835; NIHMS&PMCn/a

41.     Devalaraja M*, Wang DZ*, Ballard DW, and Richmond A. 1999. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Research. 1999 Mar 15;59(6):1372-1377. PMID10096573; NIHMS&PMCn/a

42.     Yang W*, Wang D*, Richmond A. 1999. Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization and signal transduction. Journal Biological Chemistry. 1999 Apr 16;274(16):11328-11333. PMID10196223; NIHMS&PMCn/a

43.      Haghnegahdar H, Du J, Wang D*, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R*, Richmond A. 2000. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol. 2000 Jan;67(1):53-62. PMID10647998; NIHMS49434; PMC2669312

44.      Richmond A, Kaempfer R. 2000. Cytokines revisited at Hilton head.PMID10817967; NIHMS&PMCn/a Cytokine Growth Factor Rev. 2000 Sep;11(3):255-66.

45.      Wang D*, Yang W*, Du J, Devalaraja MN*, Liang P, Matsumoto K, Tsubakimoto K, Endo T, Richmond A. 2000. MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene. 2000 Sep 21;19(40):4647-59. PMID11030154; NIHMS49436; PMC2667445

46.      Nirodi CS*, Devalaraja R*, Nanney LB, Arrindell S, Russell S, Trupin J, Richmond A. 2000. Chemokine and chemokine receptor expression in keloid and normal fibroblasts. Wound Repair Regen. 2000 Sep-Oct8(5):371-82. PMID11115149; NIHMS290749; PMC 3140346

47.      Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A, Strieter RM. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000 Nov 1;165(9):5269-77. PMID11046061; NIHM&PMCn/a

48.      Devalaraja RM*, Nanney LB, Du J, Qian Q, Yu Y, Devalaraja MN, Richmond A. 2000. Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol. 2000 Aug;115(2):234-44. Erratum in: J Invest Dermatol 2000. Nov;115(5):931. PMID10951241; NIHMS49435; PMC2664868

49.      Fan GH*, Yang W*, Wang XJ, Qian Q, Richmond A. 2001. Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. Biochemistry. 2001 Jan 23;40(3):791-800. PMID11170396; NIHMS49439; PMC2664867

50.      Wang D*, Richmond A. 2001.Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem. 2001 Feb 2;276(5):3650-9. PMID11062239; NIHMS49438; PMC2676351

51.      Nirodi C*, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A. 2001. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem. 2001 Mar 23;276(12):9366-74. PMID11112786; NIHMS290770; PMC3369623

52.      Fan GH*, Yang W*, Sai J, Richmond A. 2001. Phosphorylation-independent association of CXCR2 with the protein phosphatase 2A core enzyme. J Biol Chem. 2001 May 18;276(20):16960-8. PMID11278485; NIHMS49440; PMC2666306

53.      Luan J*, Furuta Y, Du J, Richmond A. 2001. Developmental expression of two CXC chemokines, MIP-2 and KC, and their receptors. Cytokine. 2001 Jun 7;14(5):253-63. PMID11444905; NIHM290761; PMCn/a

54.      Yang J*, Richmond A.2001. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 2001 Jun 15;61(12):4901-9. PMID11406569; NIHMS290778; PMC3140402

55.      Nirodi C*, Hart J, Dhawan P, Moon NS, Nepveu A, Richmond A. 2001. The role of CDP in the negative regulation of CXCL1 gene expression. J Biol Chem. 2001 Jul 13;276(28):26122-31. PMID11371564; NIHMS49441; PMC2665279

56.      Yang J*, Luan J*, Yu Y, Li C, DePinho RA, Chin L, Richmond A. 2001. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame. Cancer Res. 2001 Nov 15;61(22):8150-7. PMID11719444; NIHM&PMCn/a

57.      Yang J*, Fan GH*, Wadzinski BE, Sakurai H, Richmond A. 2001. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. PMC2665282 J Biol Chem. 2001 Dec 21;276(51):47828-33. PMID11591705; NIHMS49444;

58.      Du J, Luan J*, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A. 2002. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. PMC2665273 J Leukoc Biol. 2002 Jan;71(1):141-53. PMID11781390; NIHMS49447;

59.      Fan GH*, Yang W*, Sai J, Richmond A. 2002. Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. J Biol Chem. 2002 Feb 22;277(8):6590-7. PMID11751889; NIHMS49446; PMC2665275

60.      Dhawan P*, Richmond A. 2001. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem. 2002 Mar 8;277(10):7920-8. PMID11773061; NIHMS49423; PMC2668260

61.      Wang D*, Sai J*, Carter G*, Sachpatzidis A, Lolis E, Richmond A. 2002. PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry. 2002 Jun 4;41(22):7100-7. PMID12033944; NIHMS49424; PMC2668253

62.      Dhawan P*, Richmond A. 2002. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002 Jul;72(1):9-18. PMID12101257; NIHMS49425; PMC2668262

63.      Richmond A. 2002. Nf-kappa B, chemokine gene transcription and tumour growth.PMID12209135; NIHMS49426; PMC2668257 Nat Rev Immunol. 2002 Sep;2(9):664-74.

64.      Dhawan P*, Singh AB, Ellis DL, Richmond A. 2002. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.PMID12499277; NIHM&PMCn/a Cancer Res. 2002 Dec 15;62(24):7335-42.

65.      Wang D*, Sai J, Richmond A. 2003. Cell surface heparan sulfate participates in CXCL1-induced signaling. PMC2667446 Biochemistry. 2003 Feb 4;42(4):1071-7. PMID12549928; NIHMS49429;

66.      Fan GH*, Lapierre LA, Goldenring JR, Richmond A. 2003. Differential regulation of CXCR2 trafficking by Rab GTPases. Blood. 2003 Mar 15;101(6):2115-24. PMID12411301; NIHMS290780; PMCn/a

67.      Milatovic S, Nanney LB, Yu Y, White JR, Richmond A. 2003. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. 2003. Wound Repair and Regeneration May-June; 11(3): 213-219. PMID12753603; NIHMS49430; PMC2667443

68.      Fan GH, Lapierre LA, Goldenring JR, Sai J, Richmond A. 2004. Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. Mol Biol Cell. 2004 May;15(5):2456-69. PMID15004234; NIHMS49432; PMC404037

69.      Yang J*, Richmond A. 2004. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. PMC2668261 Mol Ther. 2004 Jun;9(6):846-55. PMID15194051; NIHMS49412;

70.      Amiri KI, Horton LW, LaFleur BJ, Sosman JA, Richmond A. 2004. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 2004 Jul 15;64(14):4912-8. PMID15256463; NIHMS&PMCn/a

71.      Sai J, Fan GH, Wang D, Richmond A. 2004. The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. PMC2668248 J Cell Sci. 2004 Nov 1;117(Pt 23):5489-96. PMID15479720; NIHMS49414;

72.      Walker GM, Sai J, Richmond A, Stremler M, Chung CY, Wikswo JP. 2005. Effects of flow and diffusion on chemotaxis studies in a microfabricated gradient generator. PMC2665276 Lab Chip. 2005 Jun;5(6):611-8. With Cover Photo. PMID15915253; NIHMS49416;

73.      Su YPMID16210646; NIHMS49419; PMC2668249, Raghuwanshi SK, Yu Y, Nanney LB, Richardson RM, Richmond A. 2005. Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. J Immunol. 2005 Oct 15;175(8):5396-402.

74.      Yang J, Amiri KI, Burke JR, Schmid JA, Richmond A. 2006. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways.PMID16467110; NIHMS49420; PMC2668250 Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):950-60.

75.      Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, Richmond A, Strieter R, Dey SK, DuBois RN. 2006. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. PMC2118273 J Exp Med. 2006 Apr 17;203(4):941-51. PMID16567391; NIHMS49422;

76.      Ueda Y*, Neel NF*, Schutyser E, Raman D, Richmond A. 2006. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. PMC2664111 Cancer Res. 2006 Jun 1;66(11):5665-75. PMID16740704; NIHMS49399;

77.      Sai J, Walker G, Wikswo J, Richmond A. 2006. The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. PMC2950015 J Biol Chem. 2006 Nov 24;281(47):35931-41. PMID16990258; NIHMS49401;

78.     Lee JS, Wurfel MM, Matute-Bello G, Frevert CW, Rosengart MR, Ranganathan M, Wong VW, Holden T, Sutlief S, Richmond A, Peiper S, Martin TR. 2006. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J Immunol. 2006 Dec 1;177(11):8086-94. PMID17114483; NIHMS49402; PMC2665269

79.     Amiri KI, Ha HC, Smulson ME, Richmond A. 2006. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. PMC2665274 Oncogene. 2006 Dec 14;25(59):7714-22. PMID16799643; NIHMS49400;

80.     Yang J*, Pan WH, Clawson GA, Richmond A. 2007. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. PMC2665271 Cancer Res. 2007 Apr 1;67(7):3127-34. PMID17409419; NIHMS49404;

81.     Ueda Y*, Su Y*, Richmond A. 2007. CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells.PMID17496784; NIHMS49406; PMC2665270 Melanoma Res. 2007 Apr;17(2):91-103.

82.     Yang *JM, Su YJ*, Richmond A. 2007. Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kB pathway.Free Radic Biol Med. 2007 May 1;42(9):1369-80. PMID17395010; NIHMS21364; PMC1905840

83.     Neel NFPMID17405813; NIHMS49403; PMC2766565*, Lapierre LA, Goldenring JR, Richmond A. 2007. RhoB plays an essential role in CXCR2 sorting decisions. J Cell Sci. 2007 May 1;120(Pt 9):1559-71.

84.     Schutyser E*, Su Y*, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J, Richmond A. 2007. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw. 2007 Jun;18(2):59-70. PMID17594938; NIHMS49407; PMC2665278

85.     Miller-Kittrell M, Sai J*, Penfold M, Richmond A, Sparer TE. 2007. Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1(CCMV). Virology. 2007 Aug 1;364(2):454-65. PMID17433398; NIHMS49405; PMC2665277

86.     Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, Robbins JB. 2007. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. PMC2665272 J Cutan Pathol.. 2007 Aug;34(8):593-6. PMID17640227; NIHMS49408;

87.     Horton LW, Yu Y, Zaja-Milatovic S, Strieter RM, Richmond A. 2007. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. PMC2668258 Cancer Res. 2007 Oct 15;67(20):9791-9. PMID17942909; NIHMS49409;

88.     Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin CP, Moses HL. 2008. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008 Jan;13(1):23-35. PMID18167337; NIHMS37354; PMC2245859

89.     Richmond A. 2008. CCR9 Homes Metastatic Melanoma Cells to the Small Bowel. Clinical Cancer Research. 2008, Feb 1;14(3) 621-3. PMID18245518; NIHMS&PMCn/a

90.      Dhawan PPMID18347013; NIHMS49411; PMC2397477, Su Y*, Thu YM, Yu Y, Baugher P, Ellis DL, Sobolik-Delmaire T*, Kelley M, Cheung TC, Ware CF, Richmond A. 2008. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem. 2008 May 30;283(22):15399-408.

91.      Liu Y, Sai J*, Richmond A, Wikswo J. 2008. Microfluidic Switching System for Analyzing Chemotaxis Responses of wortmannin-inhibited HL-60 cells. Biomedical Devices 2008 Aug;10(4): 499-507. PMID18205049; NIHMS49410; PMC2668251

92.      Yu Y, Su Y*, Opalenik SR, Sobolik-Delmaire T, Neel NF*, Zaja-Milatovic S, Short ST, Sai J*, Richmond A. 2008. Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. J Leukoc Biol. 2008 Aug;84(2):406-19. PMID18505935; NIHMS290790; PMC2493076

93.      Sai J*, Raman D, Liu Y, Wikswo J, Richmond A. 2008. Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. J Biol Chem. 2008 Sep 26;283(39):26538-47. PMID18662984; NIHMS290791; PMC2546539

94.      Richmond A, Su Y*. 2008. Mouse xenograft models vs GEM models for human cancer therapeutics. PMC2562196 Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82. PMID19048064; NIHMS291801;

95.      Baugher PJ PMC2576544*, Richmond A. 2008. The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. J Biol Chem. 2008 Nov 7;283(45):30868-78. PMID18755694; NIHMS291800;

96.      Pruenster M, Mudde L, Bombosi P, Dimitrova S, Zsak M, Middleton J, Richmond A, Graham GJ, Segerer S, Nibbs RJ, Rot A. 2009. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol. 2009 Jan;10(1):101-8. PMID19060902; NIHM291803; PMC3205989

97.      Yang J*, Zaja-Milatovic S, Thu YM*, Lee F, Smykla R, Richmond A. 2009. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. PMC3140401 Mol Cancer Ther. 2009 Mar;8(3):636-47. PMID19276165; NIHMS286886;

98.      Neel NF*, Barzik M, Raman D, Sobolik-Delmaire T*, Sai J, Ham AJ, Mernaugh RL, Gertler FB, Richmond A. 2009. VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci. 2009 Jun 1;122(Pt 11):1882-94. PMID19435808; NIHMS291805; PMC2684839

99.      Su Y*, Amiri KI*, Horton LW, Yu Y, Ayers GD, Gregory E, Kelley MC, Puzanov I, Richmond A, Sosman JA. 2010. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, anti-tumor effects, and modulation of therapeutic targets. Clin Cancer Res. 2010 Jan:16 (1): 348-357. PMID20028756; NIHM291806; PMC3205975

100. Raman D, Sai J*, Neel NF, Chew CS, Richmond A. LIM and SH3 protein-1 modulates CXCR2-mediated cell migration. PMC2856662 2010. PLoS One. Apr 19;5(4). PMID20419088; NIHMS291812;

101. Richmond A. 2010. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res PMC3140344. 2010 Jun;23(3):312-3. PMID20415714; NIHMS291813;

102. Yang J, Splittgerber R, Yull FE, Kantrow S, Ayers GD, Karin M, Richmond A. 2010. Conditional ablation of Ikkb inhibits melanoma tumor development in mice.PMID20530876; NIHMS302686; PMC2898608 J Clin Invest. 2010 Jul 1;120(7):2563-74.

103. Gruver JS, Potdar AA, Jeon J, Sai J*, Anderson B, Webb D, Richmond A, Quaranta V, Cummings PT, Chang CY. 2010. Bimodal analysis reveals a general scaling law governing nondirected and chemotactic cell motility. 2010. Biophys J. Jul 21;99(2):367-76. PMID20643054; NIHM329025; PMC2905119

104. Das ST PMC2909905, Rajagopalan L, Guerrero-Plata A, Sai J*, Richmond A, Garofalo RP, Rajarathnam K. 2010. Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. PLoS One. 2010 Jul 26;5(7):e11754. PMID20668677; NIHMS291808;

105. Rhodes LV, Short SP, Neel NF*, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. 2011. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15;71(2):603-13. PMID21123450; NIHMS291814; PMC3140407

106. Raman D, Milatovic SZ, Milatovic D, Splittgerber R, Fan GH, Richmond A. 2011 Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Toxicol Appl Pharmacol. 2011 Nov 1;256(3):300-13. PMID21704645; NIHMS305137; PMC3236026

107. Neel NF, Sai J*, Ham AJ, Sobolik-Delmaire T*, Mernaugh RL, Richmond A. 2011. IQGAP1 Is a Novel CXCR2-Interacting Protein and Essential Component of the "Chemosynapse". PLoS One. 2011;6(8):e23813. PMID21876773; NIHM327660; PMC3158102

108. Hawkins OE, Richmond A. 2012. The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis.NIHMS&PMCn/a Breast Cancer Res. 2012 Jan 26;14(1):103. PMID22293321;

109. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. 2012. RAF265 inhibits the growth of advanced human melanoma tumors.NIHMS&PMCn/a Clin Cancer Res. 2012 Apr 15;18(8):2184-98. PMID22351689;

110. Thu YM*, Su Y, Yang J, Splittgerber R, Na S, Boyd A, Mosse C, Simons C, Richmond A. 2011. NF-kB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the B-catenin pathway. Oncogene. 2012 May 17;31(20):2580-92. PMID21963849; NIHMS319712&336066; PMC3253179

111. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. 2012. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.NIHMSn/a; PMC3335021 PLoS One. 2012;7(4):e35309. PMID22536370;

112. Yang J, Kantrow S, Sai J, Hawkins O, Boothby M, Ayers GD, Richmond A. 2012. Targeted deletion of IKKβ in myeloid cells enhances angiosarcoma growth while systemic inhibition or tumor depletion of IKKβ inhibits tumor growth. Submitted. Cancer Research.

113. Liu, Y, Su YJ, Kelley MC, Kantrow S, Splittgerber RC, Sobolik-Delmaire T, Short S, Horton LW, Amiri KI, Mosse C, Simons C, Boyd A, Escdesy, J, Sosman J, Richmond A. 2011. Molecular targeting inhibition of aurora kinase A significantly blocks advanced human melanoma growth in a pre-clinical xenograft model. In preparation for J Clin Invest. As of 3/2012

114. Feng Y, Catalano P, Su Y, Horton L, Giantonio B, Chapman W, Hamilton S, Richmond A. Berlin J. 2011. A Phase II trial of Bortezomib plus doxorubicin in hepatocellular carcinoma. In preparation for Clin Cancer Res.

 

Publications - Chapters/Review (Asterisk* indicates graduate student or postdoctoral fellow in Ann Richmond’s lab)

115.    Chawla RK, Miller FW, Lawson DH, Richmond A, Nixon D, Rudman DH. 1981. Urinary EDC1 as an immunodiagnostic agent in breast cancer. Workshop in Immunodiagnosis of Cancer Proceedings, NIH/EPA/NIOHS, Washington, D.C., 1981. PMID& NIHMS&PMCn/a

116.    Richmond A, Lawson DH, Nixon DW. 1982. Release of an autostimulatory growth activity by human malignant melanoma cells. Cold Spring Harbor Conference: Cell Proliferation, 9:855-897, 1982. PMID&NIHMS&PMCn/a

117.    Lawson DH, Richmond A, Nixon DW, Rudman D. 1982. Metabolic approaches to cancer cachexia. Annual Reviews of Nutrition. 1982;2:277‑301. PMID6212117; NIHMS&PMCn/a

118.    Richmond A, Thomas HG*, Roy RG. 1987. Separation of melanoma growth stimulatory activity and human type-alpha transforming growth factor. Peptide Growth Factors (eds. D. Sirbasku and D. Barnes) .Methods Enzymol. 1987;146:112-26. PMID3479673; NIHMS&PMCn/a

119.    Richmond A, Thomas HG*. 1988. Melanoma growth stimulatory activity-isolation from human melanoma tumors and characterization of tissue distribution. Growth Regulation of Cancer, edited by M.E. Lippman, UCLA Symposia vol. 74, Allan R. Liss, Inc., New York, p. 71. PMID&NIHMS&PMCn/a

120.    Bordoni R*, Thomas HG*, Richmond A. 1989. Interaction of melanoma growth stimulatory activity with other growth factors and regulation of messenger RNA expression in melanoma cells. Growth Factors and Their Receptors: Genetic Control and Rational Application. pp173-180. PMID&NIHMS&PMCn/a

121.    Thomas HG*, Han JH*, Balentien E*, Bordoni R*, Richmond A. 1991. Melanoma growth stimulatory activity. Peptide Growth Factors, Part C. Methods in Enzymology (eds. D. Barnes, J.P. Mather, G.H. Sato). 198, 373-383. PMID&NIHMS&PMCn/a

122.    Richmond A. 1991. Growth and differentiation in melanocytes. Molecular and Cellular Approaches to the Control of Proliferation and Differentiation (eds. G.S. Stein and J.B. Lian), 269-295. PMID&NIHMS&PMCn/a

123.    Shattuck RL*, Balentien EG*, Richmond A. 1991. Melanoma growth stimulatory activity - a modulator of melanocyte proliferation, neutrophil chemotaxis, and tumor progression. Progress in Leukocyte Biology 11:111-116. PMID&NIHMS&PMCn/a

124.    Richmond A. 1996. MGSA/GRO proteins: physiology, biology, structure/function, role in disease. Chemokines (CRC Press, Richard Horuk, editor), 87-124. PMID& NIHMS&PMCn/a

125.    Richmond A, Mueller S*, White JR, Schraw WP. 1997. C-X-C chemokine receptor desensitization is mediated through ligand enhanced receptor phosphorylation on serine residues. Chemokines and Chemokine Receptors (ed. R. Horuk) Methods in Enzymology, 288:3-15. PMID9356983; NIHMS&PMCn/a

126.    Shattuck RL*, Richmond A. 1998. Melanoma growth stimulatory activity. in human cytokines. Handbook for Basic and Clinical Research. Vol. III (e d. BB Aggarwal), pp266-313. PMID&NIHMS&PMCn/a

127.    Richmond A, Haghnegahdar H, Shattuck-Brandt R*, Wood LD*, Nirodi CS*, Owen JD*, Strieter R, Burdick M, Luan J*. 1999. The role of melanoma growth stimulatory activity in melanoma tumorigenesis and angiogenesis. Chemokines and Cancer, Humana Press (ed BJ Rollins) pp169-189. PMID&NIHMS&PMCn/a

128.    Richmond A, Luan J*, Du J, Haghnegahdar H. 1999. The role of chemokines in wound healing and melanoma biology. Chemokines in Disease. Humana Press (ed. Caroline Hebert)Chapter 13:191-214. PMID&NIHMS&PMCn/a

129.    Devalaraja M*, Richmond A. 1999. Multiple chemotactic factors: fine control or redundancy. Trends in Pharmacological Sciences. 1999:20(4)236: 151-156. PMID10322500; NIHMS&PMCn/a

130.    Richmond A, Yang W*, Devalaraja MND. 1999. Chemokine receptor signal transduction mechanisms. Chemokines and Allergic Disease. (Ed. Marc Rothenberg), Marcel Dekker Inc. 15: 311-338. PMID&NIHMS&PMCn/a

131.    Wang D*, Richmond A. MGSA/GRO. 1999. On-line Cytokine book. (Ed. J.J. Oppenheim), Academic Press, Chapter 9. PMID&NIHMS&PMCn/a

132.    Amiri KI*, Richmond A. 2003. Fine tuning the transcriptional regulation of the CXCL1 chemokine. PMC3140403 Prog Nucleic Acid Res Mol Biol. 2003;74:1-36. PMID14510072; NIHMS49431;

133.    Fan GH, Richmond A. 2004. Chemokine Receptors. Encyclopedia of Biological Chemistry. (W.J. Lennarz & M.D. Lane, eds) Elsevier, Oxford, Vol 1, pp 413-418. PMID&NIHMS&PMCn/a

134.    Richmond A, Fan GH, Dhawan P, Yang J. 2004. How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Foundation Symposium. 2004;256:74-89; discussion 89-91, 106-11, 266-9. PMID15027484; NIHM327653; PMCn/a09/11

135.    Schutyser E, Richmond A, Van Damme J. 2005. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005 Jul;78(1):14-26. PMID15784687; NIHMS49415; PMC2665283

136.    Amiri KI*, Richmond A. 2005. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005 Jun;24(2):301-13. PMID15986139; NIHMS49417; PMC2668255

137.    Neel NF*, Schutyser E, Sai J, Fan GH, Richmond A. 2005. Chemokine receptor internalization and intracellular trafficking. 2005. Cytokine Growth Factor Rev. 2005 Dec;16(6):637-58. PMID15998596; NIHMS49418; PMC2668263

138.    Ueda Y*, Richmond A. 2006. NF-kappaB activation in melanoma. Pigment Cell Res. 2006 Apr;19(2):112-24. PMID16524427; NIHMS49421; PMC2668252

139.    Baugher P*, Richmond A. 2007. CXC Chemokines. Encyclopedia of Cancer. (Ed Manfred Schwab, Springer-Verlag, NY,) pp 787-789. PMID&NIHMS&PMCn/a

140.    Raman D, Baugher PJ*, Thu YM*, Richmond A. 2007. Role of chemokines in tumor growth. Cancer Lett. 2007 Oct 28;256(2):137-65. PMID17629396; NIHMS32005; PMC2065851

141.    Zaja-Milatovic S, Richmond A. 2008. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol. 2008 Nov;23(11):1399-407. PMID18785122; NIHMS295022; PMC3140405

142.    Yang J*, Richmond A. 2009. Monitoring NF-kappaB mediated chemokine transcription in tumorigenesis. Methods Enzymol. 2009;460:347-55. PMID19446734; NIHMS291823; PMC3140415

143.    Raman D, Neel NF*, Sai J, Mernaugh RL, Ham AJ, Richmond AJ. 2009. Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Methods Enzymol. 2009;460:315-30. PMID19446732; NIHMS291825; PMC3140414

144.    Richmond A, Yang J, Su Y. 2009. The good and the bad of chemokines/chemokine receptors in melanoma. J Pigment Cell and Melanoma Res. 22: 175-186. PMID19222802; NIHMS189486; PMC2848967

145.    Wang D, Dubois RN, Richmond A. 2009. The role of chemokines in intestinal inflammation and cancer.PMID19734090; NIHMS138266; PMC2787713 Curr Opin Pharmacol. 2009 Dec;9(6):688-96.

146.    Lazennec G PMC2840699, Richmond A. 2010. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010 Mar;16(3):133-44. PMID20163989; NIHMS180246;

147.    Thu YM*, Richmond A. 2010. NF-κB inducing kinase: a key regulator in the immune system and in cancer. PMC2939163 Cytokine Growth Factor Rev. 2010 Aug;21(4):213-26. PMID20685151; NIHMS2939163;

148.    Richmond A PMC3056356. 2011. Chemokine research moves on. Exp Cell Res. 2011 Mar 10;317(5):553-5. PMID21241691; NIHMS266341;

149.    Raman D, Sobolik-Delmaire T, Richmond A. 2011. Chemokines in health and disease. PMC3063402 Exp Cell Res. 2011 Mar 10;317(5):575-89. PMID21223965; NIHMS264758;

Richmond A (Editor). Chemokine Research Moves On. 2011. Special Edition Review Compilation for Exp Cell Research. 10 March 2011, 317(5): 553-555, 2011. (NoPMID/PMC)

Copyright © 2014 by Vanderbilt University Medical Center    |    1211 Medical Center Drive    |    Nashville, TN 37232    |    (615) 322-5000
Vanderbilt University is committed to principles of equal opportunity and affirmative action.
This page was last updated June 21, 2012 and is maintained by Lab Richmond's